New Listings: The Asset Manager Has Become the Asset

Somewhere along the way, an asset management firm stopped being the thing that builds the products and became the thing the products are built on.

T-REX 2X Long ASST Daily Target ETF (ASSX, Cboe)

The underlying here is Strive, which is an asset manager. It runs something like a dozen ETFs and collective trusts and a direct indexing platform. It is also a Bitcoin treasury company, holding tens of thousands of coins, with a preferred line paying a double-digit rate on top.

So consider the structure of the position now available to you. A leveraged ETF listed on one exchange, on a company listed on another, whose business is running ETFs, whose balance sheet is a leveraged bet on Bitcoin. Individually, each layer has a coherent rationale. Stacked, they form something closer to a wiring diagram than an investment.

What I admire most is the symmetry. A firm that builds funds is now the underlying of somebody else's fund, and the somebody else has doubled it. The industry has developed a taste for eating its own tail, and it turns out the tail rebalances daily.

Calamos Timpani Active SMID Growth ETF (CTAG, Texas Stock Exchange)

Mutual fund conversions are usually the dullest events in the industry. A strategy that already existed, run by the same team, moves into a cheaper wrapper. Nobody writes about them, which is roughly the point.

This one is worth a second look for one reason: it is listing in Texas. Not NYSE Arca, not Nasdaq, not Cboe. A long-running small and mid-cap growth strategy from a Chicago manager is arriving on the newest venue in the United States, which needs listings the way a new restaurant needs diners.

That is how exchange competition actually shows up, incidentally. Not with a press release about disruption, but with an unglamorous active equity fund quietly agreeing to be somebody's proof of concept. Somewhere a listings team is extremely pleased, and rightly so.

T. Rowe Price Biotech, Mid-Cap Equity Research and Small-Cap ETFs (TDNA, TMID, TSEE, Nasdaq)

Three active equity funds from one house at once, and credit where it is due on the first of them. T. Rowe puts a T at the front of everything it lists, which leaves three letters to say what the fund does. For a biotech fund, DNA is the only correct answer. No forced acronym, no vowels dropped to make a word fit, no fruit. In an industry that recently produced two separate funds named after a mango, TDNA counts as restraint.

The lineup does raise a question of internal geometry. T. Rowe already runs a healthcare fund that its own marketing describes as having a focus on biotechnology, though its prospectus is a broad sector mandate, and a small-midfund that covers both halves of the range by definition. The new arrivals carve biotech out as its own thing and separate small from mid. Whether this is precision or subdivision depends largely on whether you are the client or the salesperson.

The middle one is the most interesting, and not for the reason you would guess. The Equity Research funds are not a new idea here: there are already US, international and emerging markets versions. They work by handing stock selection to the analysts who cover each industry, with portfolio managers overseeing the shape rather than picking the names. What is new is that the model is now moving down the cap scale, into the part of the market where analyst coverage is thinnest and therefore, arguably, where having your own analysts matters most. That is a more coherent thought than the name suggests.

Fidelity US Fundamental Large-Cap Growth UCITS ETF (FFLG, London Stock Exchange)

A European version of a strategy Fidelity already runs in the US: active large-cap growth, Russell 1000 Growth as the reference, a reasonable charge for something with human beings making the decisions. Sensible product logic, cleanly executed.

Now the part that will irritate anyone who maintains a security master. Fidelity already has a US-listed fund using this exact ticker. Same four letters, same headline charge, same benchmark family, entirely different fund in an entirely different domicile on an entirely different exchange. And the new UCITS fund itself trades under a different ticker again on its own sterling line at the same venue.

None of this is wrong. Tickers were never unique across venues and never will be. It is simply a reminder that if you are matching on ticker, you are not matching. You are guessing with extra steps.

The naming, meanwhile, continues to strain. The European range now offers Fundamental Large Cap Core, Fundamental Small-Mid Cap and Fundamental Large Cap Growth. There are only so many words for "we pick good stocks", and the good ones went years ago.

iShares MSCI EM Latin America UCITS ETF (LAMT, Euronext Amsterdam)

And then, at the end, this. A new accumulating share class of a fund that has been tracking Latin American equities for the better part of two decades, at 20 basis points. One region. No leverage, no daily reset, no treasury strategy, no new venue to prove itself on.